Trial
NCT05602727
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Alzheimer's Disease
Intervention
MK-1942
Why stopped
Voluntarily terminated due to benefit/risk assessment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-12-10